As Patent Expiries Take Their Toll On Small Molecule Blockbuster Drugs Big Pharma Are Turning To Biologic Therapies To Drive Future Growth.DUBLIN Dublin, city, Republic of Ireland Dublin, Irish Baile Átha Cliath, county borough (1991 pop. 915,516), Leinster, capital of the Republic of Ireland, on Dublin Bay at the mouth of the Liffey River. , Ireland Ireland, Irish Eire (âr`ə) [to it are related the poetic Erin and perhaps the Latin Hibernia], island, 32,598 sq mi (84,429 sq km), second largest of the British Isles. -- Research and Markets (http://www.researchandmarkets.com/reports/c46039) has announced the addition of "Biologic Drugs to Drive Pharmaceutical Market Growth" to their offering. As patent expiries take their toll on small molecule blockbuster drugs A blockbuster drug is a drug generating more than $1 billion of revenue for its owner each year. The search for blockbusters has been the foundation of the R&D strategy adopted by big pharmaceutical companies, but this looks set to change. Big Pharma are turning to biologic therapies to drive future growth. Alliances and partnerships will be a key strategy in gaining access to the technology needed to successfully penetrate this market Scope of this title: -An overview of our forecasts for the biologic therapy sales of the leading pharmaceutical companies -Discussion of the leading Big Pharma players operating in this area -A review of the evolution in antibody engineering which is currently driving the growth of this area Highlights of this title: Biologic therapies will drive the majority of the Big Pharma companies sales growth to 2010, based on our forecasts. Of these therapies monoclonal antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). will be the key sales drivers. Reasons to order your copy: -Benchmark the presence of the Big Pharma companies in the biologics market place -Assess the key strategies that companies are using to gain access to the necessary technologies Topics Covered: -The growth of biologics is set to change the pharmaceutical market in the future -Biologics will drive Big Pharmas ethical sales growth -A number of key competitive forces are driving the success biological therapies -Pharma companies are reliant on third parties to successfully penetrate the biologic sector -Competitive position of big pharma players in biologics sector -Case study: Roche alliance with Genentech has provided it with a strong foothold foot·hold n. 1. A place providing support for the foot in climbing or standing. 2. A firm or secure position that provides a base for further advancement. foothold Noun 1. in the biologics sector -Amgen: the one that got away -Monoclonal antibody therapies antibody therapy Clinical immunology Any therapeutic intervention in which a monoclonal or other concentrated antibody is used to manage a condition–eg, cancer or severe infection are the key growth drivers -The evolution of antibody engineering technology is fuelling the growth of the monoclonal antibodies sector -The lifecycle of monoclonal antibody therapies Monoclonal antibody therapy is the use of monoclonal antibodies (or Mab) to specifically target cells. The main objective is stimulating the patient's immune system to attack the malignant tumor cells and the prevention of tumor growth by blocking specific cell receptors. are longer because of the lack of biosimilar competition Companies Mentioned: -Roche -Genentech -Amgen For more information visit http://www.researchandmarkets.com/reports/c46039 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion